MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012)

• Status: Completed
• Trial end date: 2011-06-01

Summary

This study seeks to demonstrate that additional gain in bone mineral density (BMD) can be achieved by switching to MK-5442 from an oral bisphosphonate in participants who have been receiving oral bisphosphonate therapy for at least 3 years.

• Phase: Phase 2

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Alendronate; Calcium; Calcium Carbonate; Calcium, Dietary; Cholecalciferol; Diphosphonates; Ergocalciferols; Vitamin D; Vitamins